Amanda B. Lasnik

719 total citations
14 papers, 545 citations indexed

About

Amanda B. Lasnik is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Amanda B. Lasnik has authored 14 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 6 papers in Infectious Diseases and 5 papers in Virology. Recurrent topics in Amanda B. Lasnik's work include HIV Research and Treatment (5 papers), Herpesvirus Infections and Treatments (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Amanda B. Lasnik is often cited by papers focused on HIV Research and Treatment (5 papers), Herpesvirus Infections and Treatments (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Amanda B. Lasnik collaborates with scholars based in United States and Netherlands. Amanda B. Lasnik's co-authors include Kenneth E. Palmer, J. Calvin Kouokam, Alison A. McCormick, Paul Brosio, Mark L. Smith, John A. Lindbo, Long V. Nguyen, Robert A. Mitchell, Kavitha Yaddanapudi and John W. Eaton and has published in prestigious journals such as The Journal of Immunology, Scientific Reports and Journal of Controlled Release.

In The Last Decade

Amanda B. Lasnik

14 papers receiving 538 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda B. Lasnik United States	11	194	180	109	97	95	14	545
Willem A. de Jongh Denmark	12	425 2.2×	182 1.0×	47 0.4×	62 0.6×	80 0.8×	20	761
Ina Baļķe Latvia	12	128 0.7×	112 0.6×	98 0.9×	100 1.0×	125 1.3×	26	484
Luciana D’Apice Italy	14	235 1.2×	233 1.3×	137 1.3×	150 1.5×	39 0.4×	29	582
Maria Trovato Italy	13	196 1.0×	223 1.2×	154 1.4×	89 0.9×	30 0.3×	21	543
Amit A. Upadhyay United States	11	283 1.5×	139 0.8×	58 0.5×	44 0.5×	24 0.3×	17	487
Murray Skinner United Kingdom	16	93 0.5×	142 0.8×	65 0.6×	32 0.3×	45 0.5×	43	650
Royce A. Wilkinson United States	17	521 2.7×	196 1.1×	452 4.1×	95 1.0×	105 1.1×	31	1.2k
Christine Ludwig Germany	10	342 1.8×	98 0.5×	188 1.7×	64 0.7×	32 0.3×	12	577
Magda Marquet France	12	583 3.0×	166 0.9×	107 1.0×	141 1.5×	95 1.0×	16	875
Spyros Charonis United States	8	527 2.7×	135 0.8×	116 1.1×	48 0.5×	78 0.8×	15	671

Countries citing papers authored by Amanda B. Lasnik

Since Specialization

Citations

This map shows the geographic impact of Amanda B. Lasnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda B. Lasnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda B. Lasnik more than expected).

Fields of papers citing papers by Amanda B. Lasnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda B. Lasnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda B. Lasnik. The network helps show where Amanda B. Lasnik may publish in the future.

Co-authorship network of co-authors of Amanda B. Lasnik

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda B. Lasnik. A scholar is included among the top collaborators of Amanda B. Lasnik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda B. Lasnik. Amanda B. Lasnik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Batra, Lalit, Maryam Zahin, Amanda B. Lasnik, et al.. (2025). Mucosal and Serum Neutralization Immune Responses Elicited by COVID-19 mRNA Vaccination in Vaccinated and Breakthrough-Infection Individuals: A Longitudinal Study from Louisville Cohort. Vaccines. 13(6). 559–559. 2 indexed citations

Nabeta, Henry W., Amanda B. Lasnik, Joshua L. Fuqua, et al.. (2022). Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis. Frontiers in Cellular and Infection Microbiology. 12. 976033–976033. 5 indexed citations

Rouchka, Eric C., Julia H. Chariker, Robert S. Adcock, et al.. (2021). Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Scientific Reports. 11(1). 15715–15715. 13 indexed citations

Nabeta, Henry W., J. Calvin Kouokam, Amanda B. Lasnik, Joshua L. Fuqua, & Kenneth E. Palmer. (2021). Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin. Microbiology Spectrum. 9(2). e0095721–e0095721. 13 indexed citations

Hamorsky, Krystal T., Phillip W. Graebing, Lin Wang, et al.. (2021). Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV Prevention. AAPS PharmSciTech. 22(3). 83–83. 10 indexed citations

Hamorsky, Krystal T., Jennifer K. DeMarco, Rachel J. Keith, et al.. (2021). Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky. Scientific Reports. 11(1). 18285–18285. 7 indexed citations

Lasnik, Amanda B., Longyun Zhang, Mohamed Y. Mahmoud, et al.. (2020). Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections. Journal of Controlled Release. 321. 84–99. 34 indexed citations

Lasnik, Amanda B., Longyun Zhang, A. Bennett Jenson, et al.. (2020). Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections. Antimicrobial Agents and Chemotherapy. 64(6). 13 indexed citations

Kouokam, J. Calvin, Amanda B. Lasnik, & Kenneth E. Palmer. (2016). Studies in a Murine Model Confirm the Safety of Griffithsin and Advocate Its Further Development as a Microbicide Targeting HIV-1 and Other Enveloped Viruses. Viruses. 8(11). 311–311. 35 indexed citations

10.

Yaddanapudi, Kavitha, Kalyani Putty, Beatriz E. Rendon, et al.. (2013). Control of Tumor-Associated Macrophage Alternative Activation by Macrophage Migration Inhibitory Factor. The Journal of Immunology. 190(6). 2984–2993. 123 indexed citations

11.

Kouokam, J. Calvin, Amanda B. Lasnik, Oded Foreman, et al.. (2013). Activity of and Effect of Subcutaneous Treatment with the Broad-Spectrum Antiviral Lectin Griffithsin in Two Laboratory Rodent Models. Antimicrobial Agents and Chemotherapy. 58(1). 120–127. 96 indexed citations

12.

Banerjee, Kaustuv, Elizabeth Michael, Dirk Eggink, et al.. (2011). Occluding the Mannose Moieties on Human Immunodeficiency Virus Type 1 gp120 with Griffithsin Improves the Antibody Responses to Both Proteins in Mice. AIDS Research and Human Retroviruses. 28(2). 206–214. 28 indexed citations

13.

Palmer, Kenneth E., A. Bennett Jenson, J. Calvin Kouokam, Amanda B. Lasnik, & Shin‐je Ghim. (2009). Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer. Experimental and Molecular Pathology. 86(3). 224–233. 27 indexed citations

14.

Smith, Mark L., John A. Lindbo, Paul Brosio, et al.. (2006). Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology. 348(2). 475–488. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact